 |
 |
 |
|
| Sponsors: New Hampshire, Vermont & Massachusetts Chapters and Sections of CLMA, AACC and CLAS | |
|
|
Dr. FLEISHER |
|
 |
NERC Presentation SummaryBIOMARKER AND TUMOR MARKER DEVELOPMENTThe use of biomarkers and tumor markers can help clinicians assess the progression or recurrence of a cancer. Biomarkers can be used to provide indirect information about genes that control the growth or death of cancer cells. This is especially important with the use of newly discovered drugs that are capable of attacking cancers based on gene function. This presentation will provide the technical background in understanding the difficultly in developing and validating new analytical tool that are used to detect and predict cancer growth and death. |
Dr Fleisher is President of the Clinical Ligand Assay Society |
|
|
Martin Fleisher, PhD, is the Chairman of the Department of Clinical Laboratories and Chief of the Clinical Chemistry Service at the Memorial Sloan-Kettering Cancer Center in New York City. Dr. Fleisher has over thirty years experience in discovery and application of new tumor markers and biomarkers for the early detection of cancer. His interest in biomarkers was initiated by the validation of Carcinoembryonic Antigen (CEA) in colon cancer. His seminal work on the relationship between breast cancer and cystic mastopathy involved over 80 analytes, and included biomarkers consisting of peptides, proteins, enzymes, hormones, immunoglobulins and trace metals. He has investigated the use of biomarkers, such as urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1(PAI-1) as prognostic markers in women with node negative breast cancer. Dr. Fleisher has spent his career in the discovery, development and clinical association of biomarkers that help in the early detection of cancer. He developed chromatographic methods for the determination of urinary metabolites used in the early detection and monitoring of neuroblastomas in children. In collaboration with his neuro-oncology colleagues he developed a panel of tumor markers in cerebrospinal fluid that help identify the presence of central nervous system tumors (leptomeningeal metastasis). He has developed and validated assays for the management of patients with B-cell dyscrasias with amyloidosis(free serum lambda and kappa light chains), biomarkers helpful in the prognostic evaluation of patients with ovarian cancer(YKL-40 and MMP-9), the use of circulating tumor cells(CTC) in patients with metastatic prostate cancer, and the development of a bone marker panel(osteocalcin, bone specific alkaline phosphatase, N-telopeptide, and Vitamin D) to detect the affects of tyrosine kinase inhibitors(imatinib)in patients with CML and GIST(NEJM May 2006). Dr. Fleisher's research focus is on the development of new, rapid, and inexpensive bioassays for detecting and monitoring cancer. |
|
©2007 Northeast Region Conference and Exhibition,
All Rights Reserved. Privacy
Policy | Legal